Main Uses and Benefits of Acenac SR

Acenac SR is a sustained-release formulation of aceclofenac, a medication belonging to the non-steroidal anti-inflammatory drug (NSAID) class. It is primarily used to manage pain and inflammation associated with various musculoskeletal and joint disorders.

Therapeutic Indications

This medication is commonly prescribed for the symptomatic relief of pain and inflammation in the following conditions:

• Osteoarthritis: A degenerative joint disease characterized by the breakdown of joint cartilage and underlying bone.
• Rheumatoid Arthritis: A chronic inflammatory disorder that typically affects the small joints in the hands and feet.
• Ankylosing Spondylitis: A type of arthritis that primarily affects the spine, causing inflammation of the spinal joints that can lead to severe, chronic pain and discomfort.

Mechanism and Benefits

The primary benefit of Acenac SR is its ability to reduce the production of prostaglandins, which are chemicals in the body that signal pain and cause inflammation. By inhibiting the cyclooxygenase (COX) enzymes responsible for prostaglandin synthesis, the medication helps to:

• Reduce Joint Pain: Alleviating the physical discomfort associated with movement or rest in chronic conditions.
• Decrease Swelling: Lowering the inflammatory response in affected tissues and joints.
• Improve Mobility: By reducing pain and stiffness, it helps individuals maintain better functional movement in their daily activities.

Sustained-Release Advantages

The "SR" in Acenac SR stands for sustained release. This formulation is designed to release the active medicinal ingredient gradually over an extended period. This delivery method aims to provide a more consistent level of the medication in the bloodstream, which may result in prolonged pain relief and a more convenient dosing schedule compared to immediate-release versions.

Who Can and Cannot Use Acenac SR? — Official Eligibility

Acenac SR (aceclofenac) is a Non-Steroidal Anti-Inflammatory Drug (NSAID) primarily for adult use in specific painful and inflammatory conditions. Eligibility for this medicine is strictly governed by medical guidelines and official regulatory documents, identifying groups who must not use the drug (contraindications) or should only use it with special caution.

Contraindicated Populations (Must Not Use)

Use of Acenac SR is contraindicated (prohibited) for individuals with the following conditions:

• Hypersensitivity to aceclofenac, other NSAIDs (e.g., aspirin), or any of the excipients.
• Active or recurrent peptic ulcer/haemorrhage or a history of related gastrointestinal bleeding or perforation.
• Severe hepatic failure or severe renal failure/impairment.
• Established congestive heart failure (NYHA II-IV), ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.
• Third trimester of pregnancy.

Use Not Recommended or Restricted

• Children and Adolescents (under 18 years): Use is generally not recommended as safety and efficacy have not been established.
• Pregnancy and Lactation: Avoided in the first two trimesters, and generally not recommended while breastfeeding.
• Fertility: Not recommended for women attempting to conceive as it may impair female fertility.
• Elderly Patients and those with mild to moderate organ impairment (hepatic or renal) require close medical surveillance and the lowest effective dose due to increased risk of side effects.

Interactions with other medicines and products

The interaction profile for Aceclofenac, the active compound in Acenac SR, is categorized based on documented effects on co-administered substances or an increased risk of adverse events, strictly according to regulatory labeling.

Interaction Classifications (High-Level)

Interaction Severity	Interacting Medicinal Products/Classes
Contraindicated Combinations	Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors
Exposure Modification Risk	Lithium, Digoxin, Methotrexate, Ciclosporin, Tacrolimus
Additive Pharmacodynamic Risk	Oral Anticoagulants (e.g., Warfarin), Corticosteroids, Antiplatelet Agents, SSRIs

Official Interaction Statements

• Co-administration with other NSAIDs is formally restricted due to an increased risk of adverse effects, particularly gastrointestinal events.
• Aceclofenac may increase the plasma concentrations of Lithium and Digoxin due to inhibition of their renal clearance.
• Co-administration with Diuretics, ACE Inhibitors, or ARBs may reduce their therapeutic effect and increases the risk of acute renal failure, a risk heightened in elderly or dehydrated patients.
• The official label specifies a mandatory separation period: Aceclofenac should not be used for 8 to 12 days following Mifepristone administration.
• Alcohol co-administration requires close medical surveillance due to the documented potential for increased gastric bleeding risk.

This structure defines the necessary regulatory constraints for Aceclofenac, focusing solely on the documented interaction outcomes without offering therapeutic or safety recommendations.

How Acenac SR Works: Mechanism of Action

Acenac SR's primary pharmacodynamic action is the competitive inhibition of Cyclooxygenase (COX) enzymes, exhibiting greater activity against the COX-2 isoform than COX-1. This molecular interaction restricts the production of prostaglandins, which function as critical lipid mediators in specific physiological pathways. The drug acts partly as a prodrug, with its active metabolite, 4'-hydroxyaceclofenac, contributing to the overall enzyme inhibition and subsequent alteration of signaling within the eicosanoid cascade.

This downstream effect influences both peripheral tissue responses and the central thermoregulatory system. The mechanism restricts the transmission of signaling from heightened mediator release, which affects local vascular responses and the excitability of peripheral sensory receptors (nociceptors). It also reduces prostaglandin concentration in the hypothalamus, altering the body's thermoregulatory set-point. This leads to altered regulation of local tissue fluid accumulation and a change in the central febrile response, restricting the physiological consequences of heightened mediator activity.

General Administration Protocol

Acenac SR is an oral medication taken as a single 200 mg sustained-release tablet once daily. The maximum total recommended daily dose for adults is 200 mg of aceclofenac. The principle of treatment involves using the lowest effective dose for the shortest duration necessary to achieve symptomatic support. This approach requires regular re-evaluation of the treatment continuation by the prescribing professional.

---

Intake Instructions

To ensure proper release of the active ingredient, the sustained-release tablet must be swallowed whole with sufficient liquid and must not be chewed or crushed. The integrity of the tablet is essential for the medication's controlled delivery design. The tablet is typically taken with or immediately after food.

---

Population-Specific Dosing

Dose modifications are required for certain populations. For patients with hepatic impairment, the starting daily dose must be reduced to 100 mg. Conversely, no general dose adjustment is required for older adults or individuals with mild renal impairment. Aceclofenac is not recommended for use in children and adolescents under 18 years, as insufficient clinical data exists for this age group.

Research evidence / Overview of Studies for Acenac SR

This section provides an overview of the research evidence and study landscape for the active ingredient Aceclofenac, which is used in Acenac SR. The findings describe group patterns observed in research.

---

Evidence for Use in Chronic Inflammatory Joint Conditions

The research base for conditions presenting with cycles of stability and flare-ups such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis relies primarily on structured Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time in Adults with chronic joint issues. Many of the RCTs utilized other established treatments as active comparators.

Researchers examined outcomes related to physical discomfort, primarily through standardized pain scales, and also monitored outcomes reflecting daily functioning or activity level using functional capacity scores. The findings describe patterns observed in the studies where the measurements were documented over the specified study period. The evidence base for these chronic conditions is classified at a coarse level.

Results apply only to the populations studied, and data for certain groups remain insufficient due to the modest sample sizes used in many individual trials. Long-term effects are not fully established for the sustained-release formulation.

---

Evidence for Use in Acute and Sub-Chronic Musculoskeletal Pain

The medicine was studied for its application in conditions associated with acute or disruptive episodes, such as certain types of acute lower back pain flares. Research explored outcomes describing episodic or acute changes, such as short-term assessments of physical discomfort and the time until rescue analgesia was needed. For sub-chronic conditions, research explored changes in outcomes reflecting daily functioning or activity level over defined time intervals, typically lasting up to two weeks.

For single-dose research scenarios, the evidence is limited, and the certainty remains low regarding findings in some fundamental acute pain models. Follow-up durations were limited in trials for acute pain flares, restricting the available information for recurrence patterns. Furthermore, some research describing data related to sub-chronic pain was derived from settings that used single-center or open-label study designs.

Key Studies & References

1. NICE Guideline NG226: Osteoarthritis: care and management
2. Aceclofenac Integrated Public Assessment Report (IPAR) [Source of general efficacy and PK profile]

Common questions about Acenac SR (FAQ)

---

Q: What is the difference between Acenac SR and regular Acenac tablets?

A: The SR (Sustained Release) formulation is engineered for continuous delivery of the active ingredient into the body, which is designed to support once-daily dosing. Regular, or immediate-release (IR), tablets typically release the medication faster and may need to be taken more frequently. The sustained-release design is intended to provide more controlled and steady concentration levels over an extended period.

---

Q: How long does Acenac SR take to start working?

A: Official information indicates that the active ingredient in Acenac SR is generally reported to begin absorption fairly quickly. While the specific onset for the SR form can vary, immediate-release forms are typically absorbed within 30 minutes to 2 hours. The sustained-release design is intended to deliver the compound gradually and predictably over the day to maintain consistent drug levels.

---

Q: Does Acenac SR cause drowsiness or fatigue?

A: Yes, regulatory documents list certain central nervous system (CNS) effects. Dizziness is a commonly reported adverse reaction, and official product information also mentions that some people may experience drowsiness or fatigue (tiredness). The potential for these effects is acknowledged in regulatory documents.

---

Q: What happens if I miss a dose of Acenac SR?

A: Patient Information Leaflets often advise that if a dose is missed, it should be taken as soon as a patient remembers. Official instructions typically state that if it is near the time for the next scheduled dose, the patient is usually directed to leave out the missed dose and continue with the regular dosing schedule. Official documents specify that a double dose should not be taken to make up for a missed one.

---

Q: Can Acenac SR affect my blood pressure?

A: Official warnings state that its use requires careful consideration of cardiovascular risk factors, including hypertension (high blood pressure). Like other NSAIDs, this medication can sometimes cause fluid retention, and patients with pre-existing heart conditions require caution and monitoring during treatment.

---

Q: Can I drive or operate machinery after taking Acenac SR?

A: Regulatory documents advise caution when driving or operating machinery. This is due to potential central nervous system (CNS) side effects like dizziness and drowsiness. If side effects such as dizziness, drowsiness, or blurred vision are experienced, regulatory documents advise patients to avoid driving or operating machinery.

---

Q: Is Acenac SR available as a generic medicine?

A: The active pharmaceutical ingredient in Acenac SR is Aceclofenac. As this compound is often manufactured by various companies, the existence of generic versions containing aceclofenac is common, indicating that generic options may be available in various markets, depending on local regulatory status.

---

Q: Can I take multivitamins or supplements while on Acenac SR?

A: Regulatory documents primarily focus on interactions with other prescription and over-the-counter medicines. However, official information suggests that patients should be cautious with any supplements that could affect blood clotting. Official guidance often recommends professional consultation regarding the use of supplements alongside prescription medications.

---

Q: How soon after stopping Acenac SR does it leave the body?

A: The time it takes for a medicine to be cleared from the body is related to its elimination half-life. For aceclofenac, the mean plasma elimination half-life is approximately 4 hours. While elimination occurs through metabolic breakdown, the key factor for clearance is the half-life.

---

Q: Does Acenac SR affect the results of any common medical tests?

A: While regulatory documents do not specify interference with general tests, they do advise mandatory monitoring for long-term users. This includes checking measurements related to renal function, hepatic function (liver enzymes), and certain blood component levels, as regulatory guidance advises monitoring for changes in these parameters during long-term use.

---

Q: Is Acenac SR habit-forming or addictive?

A: According to regulatory drug classifications, Acenac SR (aceclofenac) is categorized as a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is not listed under controlled substances or narcotics, which are the drug classes typically associated with the potential for abuse and physical dependence.

---

Q: What should I do if I suspect an interaction between Acenac SR and another medicine?

A: Regulatory documents and Patient Information Leaflets consistently state that any suspected adverse reaction or drug interaction should lead to an immediate consultation. If a patient experiences or suspects an adverse reaction or drug interaction, regulatory documents describe the appropriate step as seeking professional medical advice from a doctor or pharmacist.

---

Q: What is the difference between SR and slow-release formulations?

A: The term Sustained Release (SR) is used to describe a system that provides a steady drug concentration over an extended period. It is often used interchangeably with, or is considered a type of, other modified release terms like Extended Release (ER) or Controlled Release (CR). The shared goal of these systems is to maintain stable and consistent drug levels over an extended period.

---

Q: Are there any known visual side effects related to Acenac SR?

A: Yes, official product information mentions that the drug has the potential to cause visual disturbances or blurred vision as a side effect. If this symptom is experienced, caution is advised when performing tasks that require visual acuity.

---

Q: Does Acenac SR come with a medication guide from the regulatory agencies?

A: Yes. As a prescription medicine, Acenac SR is supplied with a Patient Information Leaflet (PIL) or package insert. This document contains detailed information on use, side effects, and storage, and has been reviewed and approved by the corresponding regulatory agency.

---

Q: Can Acenac SR be taken with certain herbal remedies?

A: While official labels focus on prescription medications, official drug labels advise caution when using NSAIDs alongside herbal supplements that possess antiplatelet activity (may affect blood clotting). This is important because such combinations may increase the documented risk of bleeding.

How to Store and Dispose of Acenac SR?

Regulatory agencies define specific conditions for the storage and disposal of Acenac SR (aceclofenac sustained-release) to maintain its stability and ensure safety.

---

Storage Requirements

Condition	Requirement
Temperature	Store below 30 C (Controlled Room Temperature is typically 20 C to 25 C).
Protection	The medicine must be protected from light, moisture, and freezing.
Container	Keep the tablets in their original packaging and ensure the container is tightly closed.
Child Safety	It is mandatory to keep the medicine out of the reach of children.

Disposal Instructions

Unused or expired tablets should be disposed of using a drug take-back program whenever available. If no take-back option exists, the medicine should be disposed of in household trash by first mixing it with an undesirable substance, sealing it in a bag, and then discarding it. Regulatory guidelines prohibit flushing Acenac SR down the toilet or pouring it into drains, as it must not enter wastewater systems.